alpha/beta antagonists Flashcards
1
Q
alpha 1 actions
A
- post synaptic
2. vasoconstriction, midriasis, GI relaxation, contraction of GI and bladder sphincters
2
Q
alpha 2 action (post synaptic)
A
- hyperpolarization of CNS cells (decreased MAC)
2. platelet aggregation
3
Q
alpha 2 (presynaptic)
A
- inhibition of NE release (negative feedback loop)
4
Q
beta 1 (post synaptic)
A
- increased cardic conduction, automaticity and contractility
5
Q
beta 2 post synaptic
A
vasodilation, bronchodilation, GI, uterine & bladder relaxation; glycogenolysis and (lipolysis=beta 3)
6
Q
beta 2 (presynaptic)
A
causes norepinephrine release
7
Q
alpha antagonists: phentolamne- 1. action 2. effects 3. uses
A
- (regitine)
1. nonselective alpha blocker
2. vasodilation, decreased systemic BP, increased HR d/t baroreceptor reflex, blocks alpha 2 leading to increased NE
3. treatment of hypertensive crisis, prevent sloughing after extravisation of sympathiomimetic drugs (pressors)
8
Q
phentolamine
- onset
- peak
- duration
- dose
A
- o: 1-2 minutes,
- p: 2 minutes
- dur: 10-15 min
- dose:
- hypertension-0.05-0.1 mg/kg IV followed by infusion of 0.1-1.0
mg/min
-antisloughing-5-10mg (0.1-0.2 mg/kg) injdecte in and or around the IV
9
Q
alpha antagonist: Phenoxybenzamine: 1. class/action 2. side effects 3. onset 4. uses 5. what might you want to add to this medication?
A
- nonselective alpha blocker
- vasodilation, orthostatic hypotension
- very slow onset
- use for control of blood pressure from pheochromocytoma (adrenal tumor of chromaffin cells), treatment for Raynauds.
- a beta blocker due to unopposed beta
10
Q
pheochromocytoma
- what is it?
- s/s (what is the diagnostic triad/quadrad)?
- testing
- what is clonidine suppression test?
A
- tumor that secretes catecholamines (usually adrenal)
- triad/quadrad= HTN, tachycardia, diaphoresis & headache
- MRI,CT, catacholamine levels, vanylmandilic acid (metabolite of catecholemine breakdown) levels, clonidine supression test
- clonidine is a central acting alpha 2 agonist, it mimics catecholamines in the brain causing innervation to adrenal medula to cause decrease in adrenal catecholamines. it does not reduce catecholamines if the patient has Pheochromocytoma
11
Q
yohimbine:
- action:
- uses:
A
- selective presynaptic alpha 2 blocker (central & periph acting)
- used to reverse sedatives (think precedex), used for idiopathic orthostatic hypotension, erectile dysfunction
12
Q
yohimbine:
- peripheral effect:
- central effect:
- why abuse risk?
- effect on MAC?
A
- peripheral effect is decreased alpha 2 adrenergic activity
- central effect is stimulation of mood and mild antidiuretic effect
- possible drug abuse risk d/t dissociative state similar to PCP
- since alpha 2 agonists decrease MAC by acting on receptors in cns, yohimbine may increase MAC by
13
Q
beta antagonists: propanolol: 1. \_\_\_ beta blocker: 2: \_\_\_ \_\_\_ of beta blockers: 3. what type of antagonism (beta 1 or 2)? 4. metablism 5. protein binding: 6. thererfore, does what with other protein bound meds?
A
- original; first beta blocker introduced
- the “gold standard” of beta blockers
- equal antagonist of beta 1 and beta 2 (contraindicated in asthmatics).
- well absorbed in GI but has extensive first pass metabolism
- extensively protein binding (90-95%).
- competes with them for binding sites (could effect coumadin levels etc.).
17
Q
esmolol
- drug class
- onset and acting
- use in laryngoscopy
- main use
- use in ECT
A
breviblock
- selective beta 1 (beta 2 at high doses)
- rapid onset, short acting
- dull sympathetic response to laryngoscopy
- management of periopertive hypertension and SVT
- prevention of HTN from ECT (therapy)
18
Q
esmolol:
- why does it burn on injection?
- why is duration so short?
- how much is excreted unchanged in urine?
- metabolites? active or inactive?
- how long do effects last?
A
- because the pH is 5 (acidic)
- it is rapidly hydrolyzed in the blood by plasma esterase (NOT plasma cholinesterase though)
- less than 1% excreted unchanged in urine
- inactive metabolites
- takes 15 minutes for HR to return to pre drug rate